Insilico Medicine
Insilico Medicine, a clinical stage biotech company powered by generative artificial intelligence (AI), is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties.
Latest Content
News
AI Aids Drug Discovery for Lyosomal Storage Disease
Artificial intelligence is becoming increasingly important in drug discovery. Advances in the use of Big Data, learning algorithms and powerful computers have now enabled researchers to better understand a serious metabolic disease.
News
Gray Hair and Wrinkles at an Early Age Led to New Treatment for a Rare Cancer
Researchers have found a way to predict which patients with sarcoma – a rare cancer of the bones and muscles – will benefit the most from a potential new treatment.
Industry Insight
Accelerating Efficient Drug Discovery With the Power of AI
To find out more about how generative artificial intelligence (AI) is helping to accelerate and advance drug discovery processes, we spoke to Dr. Alex Zhavoronkov, CEO of Insilico Medicine.
Product News
Insilico Medicine Receives FDA Orphan Drug Designation for INS018_055
Insilico Medicine has announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to INS018_055 for the treatment of idiopathic pulmonary fibrosis.
News
AlphaFold and AI Accelerate Design of New Liver Cancer Drug
A new study has successfully used AlphaFold, an artificial intelligence (AI)-powered protein structure database, to accelerate the design and synthesis of a drug to treat the most common type of primary liver cancer.
Industry Insight
Research Collaboration Yields New Treatment Possibilities for ALS
Frank Pun discusses how scientists from Insilico Medicine identified numerous unreported potential therapeutic targets of amyotrophic lateral sclerosis using the company’s proprietary AI-enabled biological target discovery platform.
Industry Insight
The Impact of Funding on Longevity Research
To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.
Advertisement
